Yuanyuan Qiao | Prostate Cancer Research | Innovative Research Award

Published on by Cell Biologist

 

Innovative Research Award

Yuanyuan Qiao
University of Michigan, United States

Yuanyuan Qiao
Affiliation University of Michigan
Country United States
Scopus ID 56018160800
Documents 42
Citations 2,091
h-index 21
Subject Area Prostate Cancer Research
Event World Cell Biologist Awards
Google Scholar dGln_v4AAAAJ

Yuanyuan Qiao, affiliated with the University of Michigan in the United States, is recognized in the context of the Innovative Research Award for research associated with prostate cancer. The supplied bibliographic profile identifies 42 documents, 2,091 citations, and an h-index of 21 in Scopus. These metrics provide a quantitative overview of the indexed research record and should be interpreted in relation to publication field, career stage, collaboration patterns, and database coverage. [1]

Abstract

Yuanyuan Qiao of the University of Michigan in relation to the Innovative Research Award at the World Cell Biologist Awards. The profile focuses on the supplied bibliometric record and the stated research subject of prostate cancer research. Scopus information provided for the profile reports 42 indexed documents, 2,091 citations, and an h-index of 21. [1] These indicators describe measurable aspects of scholarly visibility but do not, by themselves, establish the quality, novelty, or clinical significance of individual studies.

Keywords

Yuanyuan Qiao; Innovative Research Award; prostate cancer research; cancer biology; biomedical research; cell biology; oncology; translational research; University of Michigan; research impact; bibliometrics; scholarly publications.

Introduction

Prostate cancer is a major area of biomedical research involving molecular biology, cellular regulation, tumor development, diagnosis, treatment, and disease progression. Contemporary research in this field integrates cellular and molecular approaches with clinical and translational investigation. [4]

Within this broad research environment, scholarly profiles can be evaluated using publication records, citation counts, h-index values, and other indicators. Scopus provides author-level bibliographic information that can assist in examining indexed scholarly output, although bibliometric indicators vary according to database coverage and citation practices between disciplines. [1]

Research Profile

Yuanyuan Qiao with the University of Michigan and identifies prostate cancer research as the principal subject area for this recognition profile. The Scopus author identifier supplied for the researcher is 56018160800. The corresponding indexed record reports 42 documents, 2,091 citations, and an h-index of 21. [1]

Research Contributions

Yuanyuan Qiao’s research within prostate cancer research, a multidisciplinary field in which cellular and molecular mechanisms are relevant to understanding tumor biology and developing improved approaches to disease management. [4] Because specific publications, experimental findings, patents, clinical studies, or research projects were not supplied for this profile, individual scientific contributions are not assigned beyond the documented subject-area classification.

Publications

The supplied data indicate 42 documents indexed in Scopus. [1] A complete publication-by-publication bibliography was not included in the source information provided for this article; therefore, individual article titles, journals, publication years, authorship positions, and DOI identifiers are not attributed to Yuanyuan Qiao without direct bibliographic evidence.

Research Impact

Based on the supplied Scopus figures, the research profile has accumulated 2,091 citations across 42 indexed documents and has an h-index of 21. [1] These indicators suggest measurable citation visibility within the indexed scholarly literature. However, citation-based measures should be considered alongside qualitative evidence, including research originality, methodological contribution, reproducibility, collaboration, societal relevance, and influence on subsequent research.

Award Suitability

The supplied profile is presented for consideration under the Innovative Research Award of the World Cell Biologist Awards. Its documented alignment with prostate cancer research, together with the supplied bibliometric record, provides a basis for presenting the researcher as a candidate within an academic recognition context. [3]

Award suitability should ultimately be determined using the official award criteria and the complete nomination or application materials, including the originality of the research, significance of findings, quality of publications, evidence of scientific contribution, and broader impact. [5]

Conclusion

Yuanyuan Qiao’s supplied academic profile identifies a research affiliation with the University of Michigan and a subject focus in prostate cancer research. The reported Scopus record comprises 42 documents, 2,091 citations, and an h-index of 21. [1] These indicators provide a concise quantitative description of the indexed research record, while a comprehensive assessment of innovative research should also incorporate the scientific content and documented influence of the underlying work. [2]

References

    1. Elsevier. (n.d.). Scopus author details: Yuanyuan Qiao, Author ID 56018160800. Scopus.
      https://www.scopus.com/pages/authors/56018160800
    2. C Cheng, J Hu, R Mannan, Y Qiao, & et al. (2025). Targeting PIKfyve-driven lipid metabolism in pancreatic cancer.
      https://www.nature.com/articles/s41586-025-08917-z
    3. T He, L Xiao, Y Qiao, & et al. (2024). Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.
      https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00231-9
    4. Y Bao, Y Qiao, JE Choi, & et al (2023). Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
      https://www.pnas.org/doi/abs/10.1073/pnas.2314416120
    5. L Xiao, A Parolia, Y Qiao, & et al. (2022). Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
      https://www.nature.com/articles/s41586-021-04246-z

Varsha Rathore | Cancer Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathore’s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-Ξ² signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumor–immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289–300.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions πŸ“š – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise πŸ₯ – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants πŸ’° – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions πŸ† – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

πŸ“Œ Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

πŸŽ“ Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

πŸ’Ό Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

πŸ† Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai πŸ…

  • Shanghai Medical Leading Talent πŸŽ–οΈ

  • Shanghai Craftsman & Shanghai Medical Craftsman πŸ†

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

πŸ”¬ Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

πŸ“š Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel πŸ”¬πŸ§¬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy πŸ₯πŸ§ͺ

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway πŸ₯πŸ’Š

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer πŸ”Žβš•οΈ

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus πŸ₯πŸ”¬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma πŸ’‰πŸ”¬

  7. Proportion of Gleason Score β‰₯8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men πŸ§¬πŸ§‘β€βš•οΈ

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer πŸ©ΈπŸ›‘οΈ

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma πŸ₯πŸ“Š

πŸ… Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. πŸš€